{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T04:19:47Z","timestamp":1783657187264,"version":"3.55.0"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2008,6,16]],"date-time":"2008-06-16T00:00:00Z","timestamp":1213574400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Neurol"],"published-print":{"date-parts":[[2008,7]]},"DOI":"10.1007\/s00415-008-0839-1","type":"journal-article","created":{"date-parts":[[2008,6,12]],"date-time":"2008-06-12T08:41:53Z","timestamp":1213260113000},"page":"1045-1048","source":"Crossref","is-referenced-by-count":12,"title":["Valvular heart disease in patients with Parkinson\u2019s disease treated with pergolide. Course following treatment modifications"],"prefix":"10.1007","volume":"255","author":[{"given":"D.","family":"Dupuy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. P.","family":"Lesbre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"G\u00e9rard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Andrejak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"O.","family":"Godefroy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2008,6,16]]},"reference":[{"key":"839_CR1","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1016\/S0140-6736(04)15945-X","volume":"363","author":"Van Camp","year":"2004","unstructured":"Van Camp G, Flamez A, Cosyn B, et al. (2004) Treatment of Parkinson\u2019s disease with pergolide and relation to restrictive valvular heart disease. Lancet 363:1179\u20131183","journal-title":"Lancet"},{"key":"839_CR2","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.4065\/77.12.1280","volume":"77","author":"Pritchett","year":"2002","unstructured":"Pritchett Amandal AM, Morrison JF, Edwards WD, et al. (2002) Valvular heart disease in patients taking pergolide. Mayo Clin Proc 77:1280\u20131286","journal-title":"Mayo Clin Proc"},{"key":"839_CR3","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1212\/01.WNL.0000083985.00343.F2","volume":"61","author":"Van Camp","year":"2003","unstructured":"Van Camp G, Flamez A, Cosyn B, et al. (2003) Valvular heart disease in patients with Parkinson\u2019s disease treated with high-dose pergolide. Neurology 61:859\u2013861","journal-title":"Neurology"},{"key":"839_CR4","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1212\/01.WNL.0000129842.49926.07","volume":"27","author":"Baseman","year":"2004","unstructured":"Baseman DG, O\u2019Suilleabhain PE, Reimold SC, et al. (2004) Pergolide use in Parkinson\u2019s disease is associated with cardiac valve regurgitation. Neurology 27:301\u2013304","journal-title":"Neurology"},{"key":"839_CR5","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.4065\/80.8.1016","volume":"80","author":"Waller","year":"2005","unstructured":"Waller EA, Kaplan J, Heckman MG (2005) Valvular heart disease in patients taking pergolide. Mayo Clin Proc 80:1016\u20131020","journal-title":"Mayo Clin Proc"},{"key":"839_CR6","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1017\/S0317167100004650","volume":"33","author":"Zadikoff","year":"2006","unstructured":"Zadikoff C, Rochon P, Lang A (2006) Cardiac valvulopathy associated with pergolide use. Can J Neurol Sci 33:27\u201333","journal-title":"Can J Neurol Sci"},{"key":"839_CR7","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1002\/mds.20887","volume":"21","author":"Peralta","year":"2006","unstructured":"Peralta C, Wolf E, Alber H, Seppik K, Muller S, Bosch S, Wenning GK, Poewe W (2006) Valvular heart disease in Parkinson\u2019s disease vs controls: An echocardiographic study. Mov Disord 21:1109\u20131113","journal-title":"Mov Disord"},{"key":"839_CR8","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1097\/00045415-200211000-00005","volume":"10","author":"Serratrice","year":"2002","unstructured":"Serratrice J, Disdier P, Habib G, et al. (2002) Fibrotic valvular heart disease subsequent to bromocriptine treatment. Cardiol Rev 10:334\u2013336","journal-title":"Cardiol Rev"},{"key":"839_CR9","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1007\/s00415-007-0592-x","volume":"254","author":"Ruzicka","year":"2007","unstructured":"Ruzicka E, Linkova H, Penicka M, Ulmanova O, Novakova L, Roth J (2007) Low incidence of restrictive valvulopathy in patients with parkinson\u2019s disease on moderate dose of pergolide. J Neurol 254(11):1575\u20131578","journal-title":"J Neurol"},{"key":"839_CR10","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1016\/S0894-7317(03)00335-3","volume":"16","author":"Zoghbi","year":"2003","unstructured":"Zoghbi WA, Enriquez-Sarano M, Foster E, et al. (2003) Recommendations for evaluation of the severity of native valvular regurgitation with twodimensional and Doppler echocardiography. J Am Soc Echocardiogr 16:777\u2013802","journal-title":"J Am Soc Echocardiogr"},{"key":"839_CR11","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1136\/jnnp.66.1.79","volume":"66","author":"Shaunak","year":"1999","unstructured":"Shaunak S, Wilkins A, Philling JB, Dick DJ (1999) Pericardial, retroperitoneal and pleural fibrosis induced by pergolide. J Neurosurg Psychiatry 66:79\u201381","journal-title":"J Neurosurg Psychiatry"},{"key":"839_CR12","doi-asserted-by":"crossref","first-page":"730","DOI":"10.4065\/78.6.730","volume":"78","author":"Flowers","year":"2003","unstructured":"Flowers CM, Racoosin JA, Lu SL, et al. (2003) The US food and drug administration\u2019s registry of patients with pergolide-associated valvular heart disease. Mayo Clin Proc 78:730\u2013731","journal-title":"Mayo Clin Proc"},{"key":"839_CR13","unstructured":"FDA (2003) 2003 Safety Alert-Permax (pergolide mesylate) (http:mermax. htm\/www.fda.gov\/medwatch\/SAFETY\/2003)"},{"key":"839_CR14","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1002\/mds.20716","volume":"21","author":"Kim","year":"2006","unstructured":"Kim JY, Chung EJ, Park SW, Lee WY (2006) Valvular heart disease in Parkinson\u2019s disease treated with ergot derivative dopamine agonists. Mov Disord 21:126\u2013134","journal-title":"Mov Disord"},{"key":"839_CR15","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1212\/01.wnl.0000238508.68593.1d","volume":"67","author":"Yamamoto","year":"2006","unstructured":"Yamamoto M, Uesugi T, Nakayama T (2006) Dopamine agonists and cardiac valvulopathy in Parkinson disease: a case-control study. Neurology 67:1225\u20131119","journal-title":"Neurology"},{"key":"839_CR16","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1056\/NEJMoa054830","volume":"356","author":"Zanettini","year":"2007","unstructured":"Zanettini R, Antonini A, Gatto G, Gentile R, Tesei S, Pezzoli R (2007) Valvular heart disease and the use of dopamine agonists for Parkinson\u2019s disease. N Engl J Med 356:39\u201346","journal-title":"N Engl J Med"},{"key":"839_CR17","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1056\/NEJMoa062222","volume":"356","author":"Schade","year":"2007","unstructured":"Schade R, Anderson F, Suissa S, Haverkamp W, Garbe E (2007) Dopamine agonists and the risk of cardiacvalve regurgitation. N Engl J Med 356:29\u201338","journal-title":"N Engl J Med"},{"key":"839_CR18","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1002\/mds.20201","volume":"19","author":"Horvath","year":"2004","unstructured":"Horvath J, Fross RD, Kleiner-Fisher-Fisman G, et al. (2004) Severe multivalvular heart disease: a new complication of the ergot derivative dopamine agonists. Mov Disord 19:656\u2013662","journal-title":"Mov Disord"}],"container-title":["Journal of Neurology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-008-0839-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00415-008-0839-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-008-0839-1","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,28]],"date-time":"2019-05-28T15:08:15Z","timestamp":1559056095000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00415-008-0839-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,6,16]]},"references-count":18,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2008,7]]}},"alternative-id":["839"],"URL":"https:\/\/doi.org\/10.1007\/s00415-008-0839-1","relation":{},"ISSN":["0340-5354","1432-1459"],"issn-type":[{"value":"0340-5354","type":"print"},{"value":"1432-1459","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,6,16]]}}}